Acadia Healthcare heads into late September with a striking divergence: the stock is up 7% on the week and options traders have turned the most bullish they've been all year, yet short sellers are still sitting on 24% of the free float — one of the largest short positions in healthcare services.
The options signal is the sharpest data point this week. Call buying has overwhelmed puts to an extreme degree, with the put/call ratio collapsing to 0.32 — the lowest reading of the past year and nearly three standard deviations below its 20-day average of 0.60. That's a sharp pivot from a period stretching back through August when the PCR barely moved from the 0.62–0.68 range. Something changed this week: options traders moved from neutrality to outright bullishness, and they did it fast.
The positioning backdrop makes that call-buying surge more interesting, not less. Short interest is running at 24.1% of the free float — a high reading by any standard — yet it has eased modestly, falling about 1.9% on the week to roughly 22.2 million shares. Borrow costs are relaxed at 0.51%, and availability has loosened considerably. Three months of available shares for every two currently borrowed (availability at 224%) marks the easiest borrow conditions for ACHC in over a month, up from 127% in mid-August. There's no squeeze mechanics building here; the borrow market is comfortable. The shorts remain large and largely unmoved, while call buyers have piled in around them — an unusual combination.
Analyst sentiment leans constructive, though not uniformly. Leerink Partners lifted its target from $30 to $33 this week while keeping a Market Perform rating — supportive of higher levels, but hardly a conviction call on a stock currently at $29.37. The rest of the analyst landscape is more bullish: Guggenheim, UBS, TD Cowen, and Keybanc all carry Buy or Outperform ratings, with targets ranging from $36 to $40. Barclays sits at Equal-Weight with a $32 target, the most skeptical of the group. The mean target of $33.79 implies limited upside from here on a consensus basis, though the bulls argue the stock is still cheap at 8.5x EV/EBITDA — the bull case centers on EBITDA guidance revision momentum, M&A capacity, and the secular tailwind of expanding behavioral healthcare demand. Bears point to reimbursement risk, state-level revenue concentration, and ongoing government investigation exposure. The EPS surprise factor score of 18 is notably weak — Acadia has not been a consistent beat-and-raise story, which gives the skeptics ammunition.
The ownership picture is worth a brief mention. BlackRock added aggressively, lifting its stake to roughly 16% of shares — the largest single holder by a wide margin. Eric Khrom, who filed a 13D (activist intent) in late 2025, has since cut his position from 5.66% to 0.72% as of August 14. That's a meaningful exit from an activist posture; as with all 13D/G disclosures, the stake reflects the last-filed position, and holders falling below 5% may not file again. Farallon and UBS Asset Management both added materially last quarter. The institutional register is densely held but the activist angle has effectively closed. ORTEX's short score has held in the low-to-mid 70s all month, landing at 72.5 — elevated, consistent, and showing no sign of structural change in bear conviction even as the price recovers.
The next major catalyst is earnings on November 2. The prior quarter generated a sharp -13.9% one-day move, and the print before that moved the stock more than 8% higher — a wide range that reflects how binary results have been for this name. The interplay between the heavily bullish options positioning, a stubborn 24% short base, and a volatile earnings history is the setup worth tracking into Q3 results.
See the live data behind this article on ORTEX.
Open ACHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
